Corcept Therapeutics (CORT) News Today $73.44 +2.87 (+4.07%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Bridge City Capital LLC Has $4.80 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Bridge City Capital LLC cut its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,029 shares of the biotechnology company's stock after sJune 9 at 9:16 AM | marketbeat.comTealwood Asset Management Inc. Invests $2.26 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT)Tealwood Asset Management Inc. bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,818 shares of theJune 7 at 6:56 AM | marketbeat.comIntellectus Partners LLC Has $4.80 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Intellectus Partners LLC trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 15.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,051 shares of the bioJune 6, 2025 | marketbeat.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 5,000 Shares of StockCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $78.04, for a total transaction of $390,200.00. Following the transaction, the insider now owns 9,009 shares in the company, valued at approximately $703,062.36. This trade represents a 35.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.June 5, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 20,000 SharesCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 20,000 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $79.08, for a total transaction of $1,581,600.00. Following the completion of the sale, the insider now owns 17,705 shares of the company's stock, valued at approximately $1,400,111.40. This trade represents a 53.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.June 5, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) CEO Sells $3,314,400.00 in StockCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) CEO Joseph K. Belanoff sold 40,000 shares of Corcept Therapeutics stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $82.86, for a total transaction of $3,314,400.00. Following the sale, the chief executive officer now owns 2,901,985 shares of the company's stock, valued at $240,458,477.10. The trade was a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.June 5, 2025 | marketbeat.comCorcept's mid-stage ALS study fails to meet main goalJune 5, 2025 | msn.comCorcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis StudyJune 5, 2025 | benzinga.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $390,200.00 in StockJune 5, 2025 | insidertrades.comCorcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual MeetingJune 5, 2025 | businesswire.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by GAMMA Investing LLCGAMMA Investing LLC increased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 12,888.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,148 shJune 4, 2025 | marketbeat.comH.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy RatingJune 4, 2025 | insidermonkey.comCorcept Therapeutics (NASDAQ:CORT) Trading Down 6.2% - Here's What HappenedCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 6.2% - What's Next?June 3, 2025 | marketbeat.comPromising ROSELLA Study Boosts Buy Rating for Corcept Therapeutics with Relacorilant’s Potential in Ovarian Cancer TreatmentJune 3, 2025 | tipranks.comJuncture Wealth Strategies LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Juncture Wealth Strategies LLC purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,538 shares of the biotechnology company's stock, valued aJune 3, 2025 | marketbeat.comWhy Corcept Therapeutics Incorporated (CORT) Crashed On MondayJune 3, 2025 | msn.comBrokerages Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $138.25June 3, 2025 | americanbankingnews.comCorcept Therapeutics Incorporated (CORT)’s Reports Promising Phase 3 Results for Ovarian Cancer DrugJune 3, 2025 | insidermonkey.com1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear OfJune 3, 2025 | msn.comCorcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer TreatmentJune 3, 2025 | finance.yahoo.comCorcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian CancerJune 2, 2025 | businesswire.comZacks Research Issues Pessimistic Outlook for CORT EarningsCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Zacks Research decreased their Q1 2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued to investors on Thursday, May 29th. Zacks Research analyst K. Das now expects that the biotechnology comJune 2, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). TheJune 1, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by BrokeragesShares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) have earned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12 moJune 1, 2025 | marketbeat.comParallel Advisors LLC Has $453.73 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)Parallel Advisors LLC increased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 3.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,972,416 shares of the biotechnology company'sMay 31, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Stake Lessened by Marcum Wealth LLCMarcum Wealth LLC cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 49.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,711 shares of the biotechnology compaMay 31, 2025 | marketbeat.comVise Technologies Inc. Takes $204,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Vise Technologies Inc. bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 4,046 shares of the biotechnology company's stock, valued at approximately $204,0May 31, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CORT Q1 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Corcept Therapeutics in a research note issued to investors on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth forecasts that the biotechnology company willMay 30, 2025 | marketbeat.comZacks Research Has Pessimistic View of CORT Q2 EarningsCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research note issued to investors on Monday, May 26th. Zacks Research analyst K. Das now anMay 30, 2025 | marketbeat.comBank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Bank of America Corp DE trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 38.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,654 shares of the biotechnology company's stoMay 30, 2025 | marketbeat.comTwo Sigma Investments LP Sells 153,522 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Two Sigma Investments LP trimmed its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 202,528 shares of the biotechnology company's sMay 27, 2025 | marketbeat.com1 Growth Stock with All-Star Potential and 2 to AvoidMay 26, 2025 | finance.yahoo.comCache Advisors LLC Invests $378,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cache Advisors LLC acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 7,500 shares of the biotechnology company's stock, valued at approximatMay 26, 2025 | marketbeat.comRafferty Asset Management LLC Sells 5,606 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Rafferty Asset Management LLC decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 48.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,906 shares of the bioteMay 26, 2025 | marketbeat.comProShare Advisors LLC Purchases 7,489 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)ProShare Advisors LLC raised its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 43.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,596 shares of the biotechnology compMay 25, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment AdvisersCetera Investment Advisers reduced its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 18.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 22,048 shares of the biotechnology company's stock after selling 5,043May 25, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 150,548 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Voloridge Investment Management LLC trimmed its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 24.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 471,623 shares of the biotechnology company's stock after selling 150,May 24, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Two Sigma Advisers LPTwo Sigma Advisers LP reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 16.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 381,800 shares of the biotechnology company's stock afMay 24, 2025 | marketbeat.comTeza Capital Management LLC Makes New $212,000 Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)Teza Capital Management LLC bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,210 shares of the biotechnolMay 24, 2025 | marketbeat.comDeutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Deutsche Bank AG raised its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 48.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,600 shares of the biotechnology companyMay 23, 2025 | marketbeat.comBranded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)May 23, 2025 | msn.comTop Executive Sells Thousands in Corcept Therapeutics Stock!May 22, 2025 | tipranks.comVident Advisory LLC Sells 6,114 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Vident Advisory LLC decreased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 109,778 shares of the biotechnologyMay 22, 2025 | marketbeat.comSherbrooke Park Advisers LLC Buys Shares of 5,620 Corcept Therapeutics Incorporated (NASDAQ:CORT)Sherbrooke Park Advisers LLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 5,620 shares of the biotechnology company's stock, valued at approximately $283,000. SeMay 22, 2025 | marketbeat.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells 27,352 Shares of StockMay 21, 2025 | insidertrades.comDirector’s Major Stock Sale Shakes Up Corcept TherapeuticsMay 20, 2025 | tipranks.comMan Group plc Reduces Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Man Group plc cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 17.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 287,880 shares of the biotechnology company's stoMay 20, 2025 | marketbeat.comCORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance ReaffirmedMay 19, 2025 | finance.yahoo.comOccudo Quantitative Strategies LP Makes New $282,000 Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)Occudo Quantitative Strategies LP purchased a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,6May 19, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lessened its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 301,490 shares of the biotechnologMay 19, 2025 | marketbeat.com Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Media Mentions By Week CORT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORT News Sentiment▼0.220.68▲Average Medical News Sentiment CORT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORT Articles This Week▼1710▲CORT Articles Average Week Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Royalty Pharma News Today Jazz Pharmaceuticals News Today Perrigo News Today Supernus Pharmaceuticals News Today Nektar Therapeutics News Today Pacira BioSciences News Today Omeros News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORT) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredTrump’s treachery This might just be the greatest time in America to be an energy company. Since taking office in 2025, Presi...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CORT Stock Free CORT Stock Alerts